
Home/Insights/Korea Medical Tourism
In 2025, South Korea treated more than 2 million international patients for the first time in its history. American patient volume jumped 70.4% in a single year. Here is what the data tells us about why.
In April 2026, the South Korean Ministry of Health and Welfare released figures that marked a turning point for the global medical tourism industry: 2,011,822 international patients received care in Korea in 2025. It was the first time the country had crossed the 2 million mark, and it was not a close call. The growth was decisive, broad-based, and driven by patients from more than 200 countries.
Total medical tourism spending reached ₩12.5 trillion — approximately $9 billion USD — in 2025. The average international patient spent roughly ₩6.41 million (approximately $4,600 USD) per visit, a figure that includes medical procedures, accommodation, and associated services. These are not budget travelers looking for a discount. They are patients making deliberate, research-driven decisions about where to receive care.
Sources: Ministry of Health and Welfare (Korea), April 2026; Korea Health Industry Development Institute (KHIDI)
Among all international patient groups, American patients showed the most dramatic acceleration. 173,363 US patients sought care in Korea in 2025 — an all-time high, and a 70.4% increase year-over-year. To put that in context: that is roughly the population of a mid-sized American city choosing to fly to Seoul for medical treatment in a single calendar year.
The breakdown of what Americans came for is instructive. Dermatology led at 44.3% of US patient visits, followed by internal medicine at 13.2% and plastic surgery at 9.3%. This is a patient population seeking both elective and medically necessary care — and finding Korea's cost-to-quality ratio compelling enough to make the journey.
The cost differential is significant. Medical procedures in Korea typically cost 30 to 70% less than equivalent procedures in the United States, without compromising the standard of care. For Americans navigating a healthcare system with rising premiums, high deductibles, and limited specialist access, this gap is not a luxury consideration — it is a practical one.
The 2 million patient milestone did not happen in isolation. It is the product of deliberate infrastructure investment by the Korean government, decades of institutional excellence built by hospitals like Samsung Medical Center, Asan Medical Center, and Seoul National University Hospital, and accelerating global awareness of Korean medicine catalyzed in part by the K-culture wave.
Dermatology alone accounted for 62.9% of all foreign patients in 2025 — approximately 1.313 million people. That category grew 86.2% year-over-year. Korean dermatology clinics are not exporting a beauty trend; they are delivering physician-supervised, technology-dense medical procedures at a price point and efficiency that other markets have not replicated.
Beyond dermatology, Korea's clinical outcomes compete with the best in the world. The overall 5-year cancer survival rate stands at 73.7%, with thyroid cancer at 100.2%, breast cancer at 94.7%, and prostate cancer at 96.9%. Korea's avoidable mortality rate, 142 per 100,000, sits well below the OECD average of 237 and less than half the US figure of 336 (OECD Health at a Glance 2023). These are published statistics from verified health data, not marketing claims.
"2 million patients from 201 countries chose Korean hospitals in 2025. The question isn't why Korea. The question is why it took this long for Americans to notice."
For Korean medical institutions looking to grow their international patient base, the US market represents both the biggest opportunity and the most underserved channel. The 70.4% year-over-year growth in American patients was achieved largely without coordinated, English-language marketing investment from Korean hospitals themselves. Most American patients who traveled to Korea in 2025 did so through word of mouth, online research, or community networks — not through hospital-initiated outreach.
That gap is significant. American patients are primed and increasingly willing to consider Korean healthcare. What they need is credible, accessible information in English, structured around the questions they are actually asking: How do I find the right hospital? How do I communicate? What does the process look like from start to finish?
Korean hospitals that invest in US-facing media and content strategy now are positioning themselves ahead of what the data strongly suggests will be continued, accelerating demand. The inflection point has already happened. The question is which institutions will meet it with a presence equal to the opportunity.
If you are exploring how Korean hospitals can build meaningful awareness and patient pipelines in the US market, the US market entry guide for Korean hospitals is a useful starting point — and our team is available to walk through what a strategy looks like in practice.
All statistics cited in this article are sourced from the Ministry of Health and Welfare (Korea), Korea Health Industry Development Institute (KHIDI), and OECD Health Statistics. This article is for informational purposes only and does not constitute medical advice.
#KoreaMedical #MedicalTourismKorea #한국의료관광 #KoreanHospital
Korea treated 2.01 million foreign patients from 201 countries in 2025 — the first time the country crossed two million in a single year. (Source: Ministry of Health and Welfare, Korea, April 2026)
173,363 US patients received treatment in Korea in 2025, a 70.4% increase year-over-year. (Source: MoHW, April 2026)
Yes — the pace has accelerated sharply, from 605,768 patients in 2023 to about 1.17 million in 2024 to 2.01 million in 2025. (Source: MoHW / KHIDI)
We don't take a commission on patients. We start from the procedure, find the specialist with the best record in it, and connect you to that hospital directly. If we don't think travelling to Korea is right for your case, we'll say so.
Submit an Inquiry info@koremedconsulting.comThe statistics and medical information on this page are drawn from peer-reviewed research and recognised institutions, including the Korea Central Cancer Registry, the American Cancer Society, the Korea Health Industry Development Institute and the OECD. This content is informational only. It is not medical advice, a diagnosis, or a treatment recommendation. Outcomes vary by individual. KoreMed Consulting Group, Inc. is a marketing and consulting agency, not a licensed medical provider. For medical decisions, consult a licensed healthcare professional.